We are honored to have Tom Hassenboehler, Chief Counsel to the Energy and Power Subcommittee, U.S. House of Representatives Energy & Commerce Committee, join us to provide his thoughts and outlook on where the industry is headed in 2014. Mr. Hassenboehler manages some of the committee’s most pressing issues, including the Keystone XL pipeline and the Environmental Protection Agency’s greenhouse-gas regulations.
Topics
- Who is going to pay for grid security?
- Tax extender proposal and Senate Finance Committee markup – what impact will it have on renewable energy?
- Has energy storage found a place in the Beltway’s view of U.S. generation?
- Will the EPA allow new coal plants to be built?
- The federal government’s role in energy efficiency.
- Keystone XL and its prospects.
- Should the United States export gas/oil?
- Future of nuclear power, including waste storage.
Speakers
- Tom Hassenboehler, Chief Counsel, Energy and Power Subcommittee, U.S. House of Representatives Energy & Commerce Committee
- Jason W. Allen, Partner, Foley & Lardner LLP
- Bradley D. Jackson, Partner, Foley & Lardner LLP
- Scott Klug, Director of Public Affairs, Foley & Lardner LLP
RSVP
There is no cost to participate in this program, but pre-registration is required.
For additional information, please contact Zulaikha Rahim at zrahim@foley.com.
People
Related Insights
June 3, 2025
Foley Corporate Governance Update
Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders
On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.
September 25, 2025
Events
Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners
June 3, 2025
Health Care Law Today
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health
Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity.